

# Hydroxycarbamide (hydroxyurea)



Essential medicine status ✓

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

		<b>EMLc</b>	ATC codes: <b>L01XX05</b>
<b>Indication</b>	Chronic myeloid leukaemia, not elsewhere classified	ICD11 code: <b>2C03.2</b>	
<b>INN</b>	Hydroxycarbamide		
<b>Medicine type</b>	Chemical agent		
<b>List type</b>	Complementary		
<b>Formulations</b>	Oral > Solid > dosage form: 200 mg ; 300 mg ; 400 mg ; 500 mg ; 1 g ; 100 mg (EMLc)		
<b>EML status history</b>	First added in 2009 ( <a href="#">TRS 958</a> ) Changed in 2015 ( <a href="#">TRS 994</a> ) Changed in 2019 ( <a href="#">TRS 1021</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .		
<b>Tags</b>	<a href="#">Cancer</a>		
<b>Wikipedia</b>	<a href="#">Hydroxycarbamide (hydroxyurea)</a>		
<b>DrugBank</b>	<a href="#">Hydroxycarbamide (Hydroxyurea)</a>		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the deletion of hydroxycarbamide 250 mg solid oral dosage from the EML and EMLc, and the addition of hydroxycarbamide 100 mg solid oral dosage form to the EMLc.

